A pharmaceutical study on certain fast soluble dosage forms / (Record no. 176390)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 06260namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | EG-GICUC |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20251224130433.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 251201s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 615 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.08.08.M.Sc.2025.Na.P |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Nada Abd El Aziz Ahmed Mohammed, |
| Preparation | preparation. |
| 245 12 - TITLE STATEMENT | |
| Title | A pharmaceutical study on certain fast soluble dosage forms / |
| Statement of responsibility, etc. | by Nada Abd El Aziz Ahmed Mohammed ; Supervised Prof. Dr. Mohamed Ahmed El-Nabarawi, Prof. Dr. Mahmoud Hassan Teaima, Dr. Khaled Ibrahim El Refai |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | دراسة صيدلية على بعض الصياغات سريعة الذوبان |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2025. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 198 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (M.Sc)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 167-190. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | Cilostazol (CTZ), is a BCS class II drug with limited bioavailability. In the current study, orally disintegrating tablets (ODTs) for buccal delivery of CTZ were prepared by two methods; lyophilization (Lyo-ODTs) and direct compression (DC-ODTs). All CTZ-ODTs were evaluated for in vitro disintegration time (DT) and wetting time (WT) tests, in vitro dissolution. Scanning electron microscopic (SEM) analysis was performed for the selected Lyo-ODT-7 and DC-ODT-2. Lyo-ODT-7 composed of aerosil® 200 and PEG 4000 acquired the shortest DT (13.00 ± 0.14) and WT (33.00 ± 0.26) among the prepared ODTs. It also showed a 2.3 fold significantly enhanced dissolution profile at an early time point (5 minutes) that was maintained till 1 h, in simulated saliva fluid (pH ~ 6.8), compared to Pletaal® IR tablets (p< 0.0001). SEM analysis revealed the remarkable porosity of Lyo-ODT-7, confirming its successfully enhanced disintegration and dissolution. Lyo-ODT-7 showed significantly enhanced pharmacokinetic parameters with a 3.5 and 3.6 fold increase in Cmax (p = 0.0493) and AUC0-24 (p = 0.0470), respectively compared to Pletaal® IR tablets. The relative bioavailability of CTZ after buccal administration of Lyo-ODT-7 to rats was 364.45 %, compared to the market oral IR tablets; Pletaal®. The enhanced bioavailability imposes the successful oromucosal absorption of CTZ via buccal delivery of Lyo-ODT-7. Our study demonstrated that Lyo-ODT-7 could represent a favorable buccal dosage form for patients with intermittent claudication, suffering from dysphagia. It can also be used in cases of acute cerebral or myocardial infarction due to its significantly enhanced rate and extent of absorption. It is considered a promising approach for buccal delivery of BCS class II active pharmaceutical ingredients (APIs) suffering from solubility problems and hepatic first pass effect |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | يصنف عقار السيلوستازول BCS class II مما يحد من توافره البيولوجى. تم تحضير اقراص سريعة الذوبان مستخدمة التوصيل الفموى فى هذه الدراسة بطريقتى التجفيف بالتبريد (Lyo-ODTs) و الكبس المباشر(DC-ODTs). تم اختبار و تقييم سرعة التفكك و الابتلال و الذوبان لكل الاقراص المحضرة كما تم عمل تحليل SEM لصيغتى Lyo-ODT-7 و DC-ODT-2. ان الصيغة Lyo-ODT-7 والمتكونة من مادة الايروسيل 200 و بولى ايثيلين جيلكول 4000 حققت اسرع معدل تفكك(DT)(13.00± 0.14) وسرعة ابتلال (WT)تقدر ب (33.00±0.26) . كما اظهرت تحسن فى معدل الذوبان فى الخمس دقائق الاولى يقدر ب 2.3 ضعف المنتج التجارىPletaalو ذلك فى وسط مشابه للفم و درجة حموضة اللعاب (PH~6.8)(P < 0.0001). ان تحليل SEM اثبت مدى نفاذية الصيغة Lyo-ODT-7 مما يفسر تفوقها فى سرعة التفكك و الذوبان و كذلك ادائها الحركى فى الجسم حيث يقدر تركيز الصيغة فى الدمC max بحوالى 3.5 ضعف (P=0.0493)و يصل مدى امتصاصها و تركزها AUC 0-24الى 3.6 ضعف (p=0.0470)المنتج التجارى Pletaal. ان نسبة التوافر البيولوجى للصيغة Lyo-ODT-7 فى الفئران تقدر ب 364.45% مقارنة بالمنتج التجارى مما يؤكد نجاح الصيغة فى التوصيل الدوائى عبر الغشاء الفموى . ان هذه الدراسة توكد ان الصيغة Lyo-ODT-7 تعتبر نظام توصيل دوائى متقدم لعلاج العرج المتقطع خاصة فى المرضى الذين يعانون من صعوبة البلع. كما يمكن استخدامها فى الحالات الطارئة كالانسداد الشريانى فى المخ او القلب و ذلك لما تتمتع به من نفاذية عالية . كما ان استخدام التجفيف بالتبريد يعتبر طريقة ناجحة مقارنة بطريقة التصنيع التقليدية خاصة لفئة العقاقير BCS class IIو التى تعانى من صعوبة الذوبان و التكسير و الهضم الكبدى. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmaceutical sciences |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | العلوم الصيدلية |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Cilostazol |
| -- | buccal/oromucosal drug delivery |
| -- | porogenic ODTs |
| -- | lyophilization |
| -- | enhanced oromucosal absorption |
| -- | increased bioavailability |
| -- | improved patient compliance |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mohamed Ahmed El-Nabarawi |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mahmoud Hassan Teaima |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Khaled Ibrahim El Refai |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2025 |
| Supervisory body | Mohamed Ahmed El-Nabarawi |
| -- | Mahmoud Hassan Teaima |
| -- | Khaled Ibrahim El Refai |
| Universities | Cairo University |
| Faculties | Faculty of Pharmacy |
| Department | Department of Pharmaceutics and Industrial Pharmacy |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 01.12.2025 | 92661 | Cai01.08.08.M.Sc.2025.Na.P | 01010110092661000 | 01.12.2025 | 01.12.2025 | Thesis |